Rein therapeutics announces initiation of renew phase 2 trial of lti-03 in patients with ipf

The renew phase 2 trial will enroll up to 120 ipf patients with topline data expected in the first half of 2026 in the previously reported phase 1b study, lti-03 showed a positive trend in seven out of eight biomarkers evaluated in cohort 2, with five showing dose dependence and four showing statistically significant improvement in the combined cohort 1 and 2 data set austin, texas , may 12, 2025 /prnewswire/ -- rein therapeutics ("rein") (nasdaq: rntx), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that the renew phase 2 trial of its lead asset, lti-03, a novel, multi-pathway, caveolin-1-related peptide for the treatment of idiopathic pulmonary fibrosis (ipf), has been initiated with screening and recruitment of patients underway.  "the initiation of the renew trial in patients with ipf marks a significant step forward for rein as we prepare to ultimately identify and share the potential benefits of lti-03 on patient lung function," said brian windsor, ph.d.
RNTX Ratings Summary
RNTX Quant Ranking